

ENZO BIOCHEM

RECEIVED
CENTRAL FAX CENTER

10718391 - GAU: 1634
NO. 6954 P. 2

JAN 27 2009

PTO/SB/02a (12-05)

Approved for use through 01/31/2025, OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/718,391
Filing Date	NOVEMBER 14, 2003
First Named Inventor	DEAN L. ENGELHARDT
Art Unit	1634
Examiner Name	KATHERINE SALMON
Attorney Docket Number	ENZ-52(C2)

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Katherine Salmon/	Date Considered	04/09/2009
-----------------------	--------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, this indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JAN. 27. 2009 4:49PM

ENZO BIOCHEM

RECEIVED
CENTRAL FAX CENTER10718391 - GAU: 1634
NO. 6954 P. 3

JAN 27 2009

PTO/SB/08b (12-08)

Approved for use through 01/31/2009. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1442PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/718,391
Filing Date	NOVEMBER 14, 2003
First Named Inventor	DEAN L. ENGELHARDT
Art Unit	1634
Examiner Name	KATHERINE SALMON
Attorney Docket Number	ENZ-52(C2)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KS/	4	GAO ET AL., DIRECT IN VIVO GENE TRANSFER TO AIRWAY EPITHELIUM EMPLOYING ADENOVIRUS-POLYLYSINE-DNA COMPLEXES, HUMAN GENE THERAPY 4:17-24, 1993	
/KS/	5	WU ET AL., RECEPTOR-MEDIATED GENE DELIVERY, J. BIOL. CHEM., 263:14621-14624, 1988	
/KS/	6	CHEN ET AL., A SELF-INITIATING EUKARYOTIC TRANSIENT GENE EXPRESSION SYSTEM BASED ON COTRANSFECTION... NUCLEIC ACIDS RES. 22:2114-2120, 1994	
/KS/	7	SHILATIFARD ET AL., THE RNA POLYMERASE II ELONGATION COMPLEX, ANN REV. BIOCHEM., 72:693-715, 2003	

Examiner
Signature

/Katherine Salmon/

Date
Considered

04/09/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.